Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)

被引:104
作者
Chen, ZM
Lee, FY
Bhalla, KN
Wu, J
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Interdisciplinary Oncol, Coll Med, Tampa, FL USA
[3] Bristol Myers Squibb Oncol, Princeton, NJ USA
关键词
D O I
10.1124/mol.105.020172
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Abnormal migration and proliferation of vascular smooth muscle cells (VSMCs) are key events in the pathogenesis of restenosis that undermine the long-term benefit of widely performed balloon angioplasty and stenting procedures. Platelet-derived growth factor (PDGF) is a potent mitogen and motogen for VSMCs and is known to play a prominent role in the intimal accumulation of smooth muscle cells. In this study, we analyzed the effects of a novel protein tyrosine kinase inhibitor, BMS-354825 (dasatinib), on PDGF-stimulated VSMCs. BMS-354825 is an orally bioavailable dual Src/Bcr-Abl tyrosine kinase inhibitor currently undergoing clinical trials in cancer patients. We found that BMS-354825 inhibited PDGF-stimulated activation of PDGF receptor (PDGFR), STAT3, Akt, and Erk2 in rat A10 VSMCs and in primary cultures of human aortic smooth muscle cells (AoSMCs) at low nanomolar concentrations. The 50% inhibition of the PDGFR beta tyrosine kinase activity in vitro by BMS-354825 was observed at 4 nM. Direct comparison of BMS-354825 and another PDGFR inhibitor, imatinib (Gleevec, STI571), in VSMCs indicated that BMS-354825 is 67-fold more potent than imatinib in inhibition of PDGFR activation. BMS-354825 also inhibited Src tyrosine kinase in A10 cells. At the cell level, PDGF stimulated migration and proliferation of A10 cells and human AoSMCs, both of which were inhibited by BMS-354825 in a concentration dependent manner in the low nanomolar range. These results suggest that BMS-354825 is a potent inhibitor of PDGF-stimulated VSMC activities and a potential agent for the development of a new therapy for vascular obstructive diseases such as restenosis.
引用
收藏
页码:1527 / 1533
页数:7
相关论文
共 39 条
  • [1] Coronary restenosis: A review of current insights and therapies
    Bailey, SR
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 55 (02) : 265 - 271
  • [2] PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine
    Banai, S
    Wolf, Y
    Golomb, G
    Pearle, A
    Waltenberger, J
    Fishbein, I
    Schneider, A
    Gazit, A
    Perez, L
    Huber, R
    Lazarovichi, G
    Rabinovich, L
    Levitzki, A
    Gertz, SD
    [J]. CIRCULATION, 1998, 97 (19) : 1960 - 1969
  • [3] Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
    Bowman, T
    Broome, MA
    Sinibaldi, D
    Wharton, W
    Pledger, WJ
    Sedivy, JM
    Irby, R
    Yeatman, T
    Courtneidge, SA
    Jove, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) : 7319 - 7324
  • [4] Buchdunger E, 1996, CANCER RES, V56, P100
  • [5] Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
    Burgess, MR
    Skaggs, BJ
    Shah, NP
    Lee, FY
    Sawyers, CL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) : 3395 - 3400
  • [6] Regulation of the mitogen-activated protein kinase signaling pathway by SHP2
    Cunnick, JM
    Meng, SS
    Ren, Y
    Desponts, C
    Wang, HG
    Djeu, JY
    Wu, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (11) : 9498 - 9504
  • [7] Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2
    Cunnick, JM
    Mei, L
    Doupnik, CA
    Wu, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (26) : 24380 - 24387
  • [8] Restenosis: Repeat narrowing of a coronary artery - Prevention and treatment
    Dangas, G
    Kuepper, F
    [J]. CIRCULATION, 2002, 105 (22) : 2586 - 2587
  • [9] The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    Deininger, M
    Buchdunger, E
    Druker, BJ
    [J]. BLOOD, 2005, 105 (07) : 2640 - 2653
  • [10] Dorsey JF, 2000, CANCER RES, V60, P3127